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Adiponectin and leptin levels in
migraineurs in the Atherosclerosis Risk in
Communities Study
ABSTRACT
Objective: To evaluate adiponectin and leptin levels in older men and women with migraine.
Methods: Fasting total and high molecular weight (HMW) adiponectin and leptin levels were eval-
uated in a case–cohort study of nondiabetic older migraine and nonmigraine control participants
from the ongoing, longitudinal, general population, Atherosclerosis Risk in Communities Study at
visit 1 (1987–1989). A standardized headache questionnaire was completed at visit 3 (1993–
1995). Logistic regression models adjusted for age, sex, race, center, body mass index, and
fasting glucose were used to evaluate the association of each adipocytokine with migraine.
Results: Of the 981 participants, the mean age at baseline was 52.8 years (SE 0.3); 131 fulfilled
migraine criteria. Crude, mean total adiponectin levels were greater in men and women with
migraine (8.1 mg/mL, SE 0.5) as compared to those without migraine (7.0 mg/mL, SE 0.2) (p 5
0.031). After adjustments, the odds of migraine were increased by 88%with each SD increase in
total adiponectin in men (odds ratio [OR] 1.86; 95% confidence interval [CI] 1.15, 3.01; p 5
0.011), but not in women (OR 1.05; 95% CI 0.80, 1.37; p 5 0.728; p interaction 5 0.029).
Similar results were demonstrated for HMW adiponectin. Crude and adjusted leptin levels were
not associated with migraine.
Conclusions: Although crude, total adiponectin levels were higher in older men and women with
migraine than controls, after adjustments, the prevalence of migraine was significantly associ-
ated with total adiponectin only in older men, suggesting the association may be confounded or
absent in older women. Leptin was not associated with migraine in older men or women.
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GLOSSARY
all-Mig 5 combined group of participants with migraine and probable migraine; ARIC 5 Atherosclerosis Risk in Communities
Study; BMI 5 body mass index; CI 5 confidence interval; HMW 5 high molecular weight; ICHD 5 International Classification
of Headache Disorders; IL-65 interleukin-6; LMW5 low molecular weight;MMW5middle molecular weight;NFkb5 nuclear
factor kb; OR 5 odds ratio; prob-Mig 5 probable migraine.
Migraine is a neurologic disorder associated with obesity,1 hyperlipidemia,2 and insulin resis-
tance.3 Current theories suggest that the neurogenic inflammation4 of migraine involves neuro-
transmitters and proteins that participate in energy regulation and metabolism (e.g.,
serotonin).5,6 More recently, adipocytokines (cytokines predominantly secreted from fat cells,
such as adiponectin and leptin) have been suggested to contribute as inflammatory mediators of
migraine.7,8
While the high molecular weight (HMW) oligomer of adiponectin is largely proinflamma-
tory, the low molecular weight (LMW) oligomer is anti-inflammatory. HMW adiponectin
has been shown to activate nuclear factor kb (NFkb) and to induce interleukin-6 (IL-6).9,10
In contrast, LMW adiponectin has been shown to reduce IL-6 secretion.11
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Although adiponectin levels are decreased
in obesity states,12,13 recent studies reported
increases of adiponectin levels in migraineurs.
Specifically, these studies reported that base-
line total adiponectin levels were elevated
in reproductive-aged women with chronic
migraine7 and that levels decline in episodic
migraineurs in pain following successful treat-
ment.8 In contrast to adiponectin, plasma levels
of the adipocytokine leptin are increased in pa-
tients with obesity14; however, no changes in
leptin levels have been reported in migraineurs
after adjusting for body mass index (BMI).15,16
Recent epidemiologic research supports
that obesity in migraineurs exhibits a differen-
tial effect by age and sex, with the greatest
association in younger women (,50).17 Given
previous data demonstrating age- and sex-
specific differences in adiponectin and leptin
in healthy individuals,18,19 our aim was to eval-
uate these levels in older migraineurs. We
hypothesized that adiponectin, and not leptin,
would be elevated in older migraineurs.
METHODS Study design. The Atherosclerosis Risk in Com-
munities Study (ARIC) is a longitudinal community-based study
conducted at 4 sites (Jackson, MS; Forsyth County, NC;
Washington County, MD; suburban Minneapolis, MN). The
initial recruitment and study participation has been previously
described.20 In brief, ARIC includes a predominantly biracial
population of 15,792 adults, who upon initial recruitment were
between 45 and 64 years of age.20 The first visit occurred during
1987–1989, with visits 2 (1990–1992), 3 (1993–1995), and 4
(1996–1998) occurring approximately 3 years apart. Visit 5
occurred during 2011–2013 among surviving participants.
The current study used data from a prospective case–cohort
within ARIC, which was originally designed to investigate the
role of plasma biomarkers collected at visit 1 (1987–1989) in
the development of diabetes.21 The study also used headache
questionnaires collected approximately 6 years later at visit 3
(1993–1995). Of the 15,792 participants who attended visit 1,
the case–cohort study excluded those with prevalent diabetes
(n 5 2,018), 95 with race other than black or white, the few
black subjects from the Minnesota andWashington County sites,
853 not returning to any follow-up visit, 26 with no diabetes
determination at follow-up, and 6 with restrictions on plasma
use. Additionally, 12 were excluded for missing baseline anthro-
pometrics, 2,514 participants in a previous ARIC case–control
and case–cohort study using stored plasma, 212 for incomplete
fasting, and 315 with missing information for key covariates.22
From this population, a random cohort (n 5 591) and incident
diabetes case sample (n5 599) were sampled by race strata. Addi-
tionally, participants who were missing adiponectin levels (n 5
106) (none were missing leptin levels) and headache questionnaires
(n5 103) were excluded, leaving a total of 981 participants (figure
e-1 on the Neurology® Web site at www.neurology.org).
Ascertainment of headache status. At visit 3, trained
interviewers administered a headache questionnaire to all
participants.23,24 Participants were queried as to whether they ever
experienced headaches lasting 4 or more hours. Those reporting
never experiencing headaches lasting $4 hours were categorized
as nonmigraine controls, herein referred to as controls. Partici-
pants responding affirmatively were asked more detailed ques-
tions regarding location, quality, duration, and accompanying
symptoms including nausea or vomiting, photophobia, phono-
phobia, and if they felt like lying down in a dark room during
headaches. Additionally, participants were asked if they experi-
enced a visual aura (spots, jagged lines, or heat waves) in associ-
ation with their headaches.
Based on the responses to a headache questionnaire adminis-
tered at visit 3, migraine was characterized for these analyses using
modified International Classification of Headache Disorders
(ICHD), 2nd edition, criteria. Participants were categorized as
having migraine who fulfilled the following 4 criteria: (1) head-
ache lasting $4 hours; (2) headache with at least 2 out of the
following 3 features: (a) throbbing, pulsing, or pounding quality,
(b) unilateral location, (c) desire to go to a dark room and lie
down; (3) nausea or vomiting or both photophobia and phono-
phobia; and (4) $1 year history of headaches (at any point in
their life). Those participants with a history of headache lasting
$4 hours and satisfying 2 out of 3 of criteria of the second criteria
were categorized as probable migraine (prob-Mig). Those not
fulfilling migraine or prob-Mig criteria were categorized as con-
trols. Additional analyses were conducted for the combined group
of participants with migraine and prob-Mig (all-Mig). Finally,
subgroup analyses were conducted for migraine groups based
on the presence or absence of visual aura, with those responding
affirmatively to experiencing a visual aura categorized as with aura
and those responding negatively as without aura.
Covariates. All covariates used in the regression models were as-
sessed at visit 1.20 Covariates included age (years), sex, race/center
(Maryland whites; Minnesota whites; North Carolina whites;
North Carolina blacks; Mississippi blacks), BMI (kg/m2), and
fasting blood glucose (mg/dL). A combined race/center variable
was created to adjust for confounding between these 2 variables.
BMI was calculated as weight in kilograms/height in meters.2
Laboratory methods. Fasting plasma blood samples collected
at visit 1 (1987–1989) were centrifuged, aliquoted, and stored
at 270°C for approximately 20 years, until thawed and main-
tained at 4°C until measured (no longer than 24 hours later).22
Total and HMW adiponectin were assessed with sandwich
ELISA (American Laboratory Products Company, Salem, NH)
with a minimum assay sensitivity of 0.04 ng/mL. Pretreatment
with proteinase K, which digests all isoforms except for HMW
adiponectin, allowed for HMW adiponectin to be measured at
the same time as total adiponectin. Reliability coefficients for
total, HMW, and HMW:total adiponectin ratio were 0.93,
0.98, and 0.70, respectively.22 Leptin was measured in duplicate
using a sandwich ELISA (Linco Research, St. Charles, MI) with a
reliability coefficient of 0.94 and a minimum assay sensitivity of
0.5 ng/mL.25 Fasting glucose and cholesterol were measured
using standard laboratory techniques.26
Statistical analysis. All statistical analyses were weighted to
account for the case–cohort study design using the svy command
and pweights in Stata version 13 (StataCorp LP, College Station,
TX). This method involves inverse weighting of the observations
according to the sampling design, to permit statistical estimation
and inference relevant to the entire cohort, which adjusts for the
oversampling of incident diabetes. All standard errors were esti-
mated using the Taylor series linearization method. p Values were
calculated using linear regression and x2 test statistics.
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Means (SE) and proportions (SE) of baseline characteristics of
study participants were reported overall and by migraine category.
We examined the association of total, HMW, and the ratio of
HMW to total adiponectin and leptin with migraine using logis-
tic regression models. Odds ratios (ORs) from the logistic regres-
sion models were calculated per 1 SD increase in adipocytokine
level, where the SD was based on the random cohort sample.
Model 1 was adjusted for age, sex, race/center, and BMI. Given
the association of migraine with impaired insulin sensitivity27 as
well as the association of adiponectin with diabetes,22 model 2 was
adjusted for variables in model 1 plus fasting glucose. We for-
mally tested for multiplicative interaction by age, sex, and BMI
and present stratified results when interaction was present with a
p value,0.05. Our primary outcome was all-Mig; additionally, a
sensitivity analysis using migraine as the outcome was conducted.
Standard protocol approvals, registrations, and patient
consents. The institutional review boards of all participating
institutions approved the study, and all participants provided
written informed consent.
RESULTS Participants. Demographic, socioeconomic,
and laboratory characteristics of the 981 participants
(360 men and 621 women) are presented in table 1.
The mean age of participants was 52.8 years (SE 0.3)
(range 45–64). A total of 13.4% (131/981) of partic-
ipants met criteria for all-Mig (72 migraine, 59 prob-
Mig). Participants with all-Mig were more likely to be
female (p5 0.055) and younger (p, 0.001) and have
lower fasting glucose (p5 0.033) than controls. A total






(n 5 72) p Valuea
Prob-Mig
(n 5 59) p Valueb
All-Mig
(n 5 131) p Valuec
Age, y, mean (SE) 52.8 (0.3) 53.2 (0.3) 50.8 (0.7) 0.001 50.6 (0.3) 0.004 50.7 (0.5) ,0.001
Sex
Male 36.7 (2.2) 38.6 (2.4) 25.0 (6.6) 0.080 29.6 (8.6) 0.342 26.7 (5.2) 0.055
Female 63.3 (2.2) 61.4 (2.4) 75.0 (6.6) 70.4 (8.6) 73.3 (5.2)
Race/field center
Washington County, MD, whites 31.2 (2.1) 30.1 (2.3) 40.3 (7.5) 0.066 31.4 (8.9) 0.873 37.0 (5.7) 0.200
Minneapolis, MN, whites 27.3 (2.1) 26.4 (2.3) 34.7 (7.3) 27.7 (8.6) 32.1 (5.6)
Forsyth County, NC, whites 23.0 (2.0) 23.9 (2.2) 18.5 (6.0) 17.9 (7.5) 18.2 (4.7)
Forsyth County, NC, blacks 2.0 (0.4) 2.3 (0.4) 0.0 (0.0) 1.3 (1.3) 0.5 (0.5)
Jackson, MS, blacks 16.5 (0.7) 17.4 (1.3) 6.6 (2.1) 21.6 (5.3) 12.2 (2.4)
Education
<HS 16.3 (1.5) 16.8 (1.7) 17.5 (5.7) 0.991 6.6 (2.8) 0.085 13.4 (3.8) 0.562
HS or equivalent 45.2 (2.2) 45.6 (2.4) 44.7 (7.5) 40.4 (9.0) 43.1 (5.8)
>HS 38.5 (2.2) 37.5 (2.4) 37.8 (7.3) 53.0 (9.1) 43.5 (5.8)
Family income
<$35,000 46.9 (2.2) 47.6 (2.4) 40.8 (7.4) 0.281 46.1 (9.0) 0.307 42.8 (5.7) 0.153
‡$35,000 48.0 (2.20 46.7 (2.4) 56.2 (7.4) 52.7 (9.1) 54.9 (5.8)
Not reported 5.1 (0.9) 5.7 (1.1) 3.0 (1.4) 1.2 (0.7) 2.3 (0.9)
Smoking status
Current 18.8 (1.7) 19.6 (1.9) 12.8 (4.9) 0.382 17.7 (7.0) 0.910 14.6 (4.0) 0.418
Former 32.5 (2.1) 32.9 (2.3) 29.8 (7.0) 30.7 (8.6) 30.1 (5.4)
Never 48.8 (2.2) 47.5 57.4 (7.5) 51.6 (9.1) 55.2 (5.8)
Aura NA NA 23.0 (6.0) 12.0 (6.0) 0.044 18.7 (4.4)
BMI, kg/m2, mean (SE) 27.1 (0.2) 27.3 (0.2) 27.0 (0.7) 0.776 25.9 (0.6) 0.954 26.6 (0.5) 0.243
Hypertension 26.3 (1.8) 26.7 (2.0) 21.9 (6.1) 0.477 27.2 (7.5) 23.9 (4.7) 0.589
Standard laboratories, mean (SE) 0.317
Fasting glucose, mg/dL 99.9 (0.4) 100.3 (0.4) 97.6 (1.3) 0.047 98.9 (1.3) 0.712 98.1 (0.9) 0.033
Total cholesterol, mg/dL 210.0 (1.7) 210.4 (1.8) 208.5 (5.9) 0.755 206.5 (10.4) 207.8 (5.4) 0.638
Abbreviations: All-Mig 5 probable migraine 1 migraine; BMI 5 body mass index; HMW 5 high molecular weight; HS 5 high school; NA 5 not applicable;
prob-Mig 5 probable migraine.
Data are presented as % (SE) except where noted as mean (SE).
a Comparisons of migraine to controls.
bComparisons of prob-Mig to controls.
c Comparisons of the combined all-Mig group to controls.
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of 18.7% of participants (SE 4.4) with all-Mig had a
history of aura (table 1).
Adipocytokines. Adiponectin. As previously described in
the literature,18,28 total and HMW adiponectin levels
in our sample were higher in women (total 8.15, SE
0.23 mg/mL, HMW 3.80, SE 0.15 mg/mL) than
men (total 5.41, SE 0.21 mg/mL, p , 0.001;
HMW 2.1, SE 0.11 mg/mL, p , 0.001; table e-1).
As compared to controls, crude total adiponectin lev-
els were increased in those with all-Mig as well as those
with migraine alone but were not significantly differ-
ent in those with prob-Mig (table 2 and figure 1).
HMW adiponectin levels were nominally higher in
those with all-Mig and migraine alone, as compared
to controls, but did not reach statistical significance
(table 2, figure 1). The HMW:total adiponectin ratio
was not different across groups (table 2). Mean crude
total, HMW, and HMW:total adiponectin levels were
not different between all-Mig participants with and
without aura (table e-2).
Although there was no difference in crude, sex-
stratified adiponectin levels across migraine groups
compared to controls (table e-1), after adjustments,
the odds of all-Mig were increased by 86% in men
(OR 1.86, 95% confidence interval [CI] 1.15–
3.01) for each 1-SD increase in total adiponectin
(table 3). Similarly, after adjustment, the odds of
all-Mig was almost twofold greater in men for each
SD increase in HMW adiponectin (OR 1.96; 95%
CI 1.11, 3.48). The HMW:total ratio was not asso-
ciated with increased odds of all-Mig in men. In con-
trast, the odds of all-Mig and migraine did not
increase with increasing total, HMW, or HMW:total
adiponectin levels in women (table 3, p value, sex
interaction: total p 5 0.029, HMW p 5 0.036,
HMW:total p 5 0.537). Due to the small number
of male participants with aura (n 5 6), reliable inter-
pretation of adiponectin levels stratified by sex with
and without aura was not possible.
Leptin.As previously described in the literature,28,29
crude leptin levels were lower in men than in women,
independent of migraine status (mean leptin: women
24.6, SE 1.2 ng/mL; men 6.0, SE 0.4 ng/mL, p ,
0.001). However, crude and adjusted leptin levels
were not significantly different in any of the migraine
groups compared to controls (tables 2 and 3), and
there was no sex-specific interaction for leptin (p 5
0.293). Additionally, leptin levels did not vary in all-
Mig participants by aura status (table e-2).
DISCUSSION We conducted an analysis in the first
large general population study to investigate the asso-
ciation between migraine and adipocytokines and
present 3 main findings. First, crude total adiponectin
levels were higher in those with migraine as compared
to those without migraine. Second, there was an
interaction by sex such that increasing total adiponec-
tin was associated with increased odds of migraine in
older men, but not women. Finally, leptin did not
significantly differ in migraineurs as compared to
nonmigraine controls. Supporting our findings that
adiponectin differs by migraine status is a prior clini-
cal trial of 37 reproductive-aged women that
demonstrated higher total adiponectin levels in
women with chronic migraine7; however, no studies
have interpreted the sex-specific effect.
There are several potential explanations for the sex
interaction with adiponectin and migraine. First, it is
possible that the sex differences in the expression of
circulating total and multimeric adiponectin contrib-
ute partially to the increased risk of migraine in older
men but not women. Younger women of reproduc-
tive age have been shown to have higher total adipo-
nectin and HMW adiponectin, but comparable
LMW adiponectin levels, in comparison with youn-
ger men.18,28,30 The lower adiponectin levels in youn-
ger men may be, at least in part, due to the effects of
testosterone.31 Castrated mice have high levels of
Table 2 Crude adipocytokines levels in migraine and nonmigraine control participants in the Atherosclerosis






(n 5 72) p Valuea
Prob-Mig
(n 5 59) p Valueb
All-Mig
(n 5 131) p Valuec
Adiponectin
Total ADP, mg/mL 7.1 (0.2) 7.0 (0.2) 8.3 (0.6) 0.050 7.8 (0.7) 0.278 8.1 (0.5) 0.031
HMW ADP, mg/mL 3.2 (0.1) 3.1 (0.1) 3.7 (0.3) 0.080 3.6 (0.5) 0.320 3.7 (0.3) 0.057
HMW:total ADP 0.41 (0.01) 0.41 (0.01) 0.43 (0.01) 0.108 0.42 (0.02) 0.498 0.43 (0.01) 0.126
Leptin, ng/mL 17.8 (0.8) 17.7 (0.9) 20.6 (3.1) 0.371 14.7 (2.0) 0.194 18.4 (2.1) 0.755
Abbreviations: ADP 5 adiponectin; all-Mig 5 probable migraine 1 migraine; HMW 5 high molecular weight; prob-Mig 5
probable migraine.
Data are presented as mean (SE).
ap Values are for comparisons of migraine to controls.
bp Values are for comparisons of prob-Mig to controls.
cp Values are for comparisons of the combined all-Mig group to controls.
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plasma adiponectin and testosterone treatment
reduced plasma adiponectin.32 Further, in rat adipo-
cytes, testosterone selectively impeded HMW adipo-
nectin but not middle molecular weight (MMW) or
LMW adiponectin.33 As such, it may be that the
multimers MMW or LMW are more important for
migraine, and these levels are differentially expressed
between sexes.
It is also possible that by looking only at older mi-
graineurs, we are missing a differential sex effect by
age, in which adiponectin levels are increased in
young but not older women with migraine. Adipo-
nectin levels were shown to increase with age,
particularly in men.19,34 Whereas men over 65–70
years of age have significantly higher plasma adipo-
nectin levels than young men, women may have less
of an increase in total adiponectin with age. Thus
with age (and declining testosterone), men have a
greater increase in total adiponectin and specifically
more HMW adiponectin than older women, poten-
tially placing men with higher adiponectin at greater
risk of migraine in the age group studied.
We were not able to evaluate the LMW and
MMW adiponectin oligomers. It is possible that the
extent of the increase in the ratio of the proinflamma-
tory (HMW) to anti-inflammatory (LMW) oligomers
Figure 1 Crudemean total and highmolecular weight adiponectin levels in migraine and control participants in
the Atherosclerosis Risk in Communities Study
(A) Crude mean total and (B) high molecular weight (HMW) adiponectin levels. *p , 0.05 Compared to controls. All-Mig 5
both probable migraine and migraine; Mig 5 migraine; prob-Mig 5 probable migraine.
Table 3 Adjusted odds ratio of migraine with 95% confidence intervals in relationship to 1 SD increase in
adipocytokine level
Model 1 Model 2
Odds ratio 95% CI p Value Odds ratio 95% CI p Value
Women
Adiponectin (per 1 SD)
Total ADP 1.08 0.83, 1.39 0.570 1.05 0.80, 1.37 0.728
HMW ADP 1.04 0.82, 1.33 0.718 1.02 0.80, 1.31 0.875
HMW:total ADP 1.01 0.74, 1.39 0.941 1.00 0.72, 1.37 0.981
Leptin (per 1 SD) 1.08 0.72, 1.62 0.703 1.10 0.74, 1.63 0.651
Men
Adiponectin (per 1 SD)
Total ADP 1.88 1.18, 3.00 0.008 1.86 1.15, 3.01 0.011
HMW ADP 1.99 1.14, 3.48 0.015 1.96 1.11, 3.48 0.021
HMW:total ADP 1.16 0.73, 1.83 0.535 1.14 0.72, 1.81 0.566
Leptin (per 1 SD) 3.98 0.31, 50.71 0.286 3.96 0.28, 56.3 0.308
Abbreviations: ADP 5 adiponectin; CI 5 confidence interval; HMW 5 high molecular weight.
Model 1 adjusted for age, race/center, body mass index; model 2 adjusted for variables in model 1 plus glucose; 1 SD of
cohort: total adiponectin: 3.71 mg/mL; HMW adiponectin: 2.25 mg/mL; HMW:total adiponectin: 0.12; leptin: 22.36 ng/mL;
p value for sex interaction, model 1: total p 5 0.029, HMW p 5 0.036, HMW:total p 5 0.537, leptin p 5 0.293.
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contributes to migraine risk. Thus, as older men have
a larger increase in total and HMW adiponectin than
women, they may also have larger increases in the
HMW:LMW ratio and thus greater vulnerability to
inflammation and migraine as compared to older
women. As LMW adiponectin was not evaluated,
we were not able to test this hypothesis.
It is also possible that total and HMW adiponectin
may be only increased ictally in women with active
migraine pain, and not interictally when migraineurs
are pain-free.7 Previous studies have shown that total
and HMW adiponectin were elevated in chronic mi-
graineurs with active pain as compared to both epi-
sodic migraineurs when interictal and controls
without pain.7 In addition, a second study demon-
strated that total, HMW adiponectin, and HMW:
LMW ratio were increased during acute moderate
to severe pain in episodic migraineurs as compared
to levels after successful treatment with mild or no
pain.8 As we were unable to assess the level of
migraine pain at the time of the blood draws, it is
possible that pain severity is an unmeasured con-
founder in sex interaction in migraineurs resulting
in a missed association of adiponectin and migraine
in older women.
Leptin has been studied in relationship to
migraine in prior clinic-based studies. One study
measured leptin levels in 84 women16 and found that
although crude leptin levels were lower in migraineurs
than controls, this difference was attenuated after ad-
justing for fat mass.15 Our results show no association
with migraine and leptin, and taken together this
suggests that while leptin may participate in energy
homeostasis and modulation of inflammatory process
(e.g., modulation of NFkb), it may have less or no
direct role in the modulation of inflammation and
pain related to migraine.
Our study has several strengths. It permitted
assessment of the association between migraine and
adiponectin levels in a large biracial population-
based sample, not impacted by the limited generaliz-
ability inherent in clinical samples. Participants in a
community-based sample of older individuals allowed
investigation into associations with migraine, inde-
pendent of BMI and other rigorously measured con-
founders. Our ascertainment of migraine is in close
alignment with standardized criteria.
There are several limitations of our study. First,
migraine assessments and blood draws were done
approximately 6 years apart, thus we were not able
to determine the presence or absence of active
migraine pain at the time of the blood draw. As a
result, while we can say that in older men the risk
of migraine is increased with increasing total adipo-
nectin, because pain is unmeasured, it is not clear that
there is an absence of an association in older women
between total adiponectin and migraine. The non-
concurrent cross-sectional design permits the possibil-
ity that some participants classified as nonmigraine
controls developed migraine between visits 1 and 3,
and thus the adiponectin values would have been
drawn prior to development of migraine. It is likely
that this only occurred in a small number of partici-
pants, as migraine has the highest incidence in the
second decade of life, with a very low incidence after
age 50 years.35,36 Another consideration is that adipo-
nectin levels increase with age,17 and are likely lower
at visit 1 than would be projected 6 years later at visit
3; however, this should occur nondifferentially across
all participants included in the current analysis (i.e.,
irrespective of presence or absence of migraine).
Second, adiponectin is a complex hormone with
respect to its role in inflammation, with both proin-
flammatory and anti-inflammatory properties, de-
pending on the oligomers and ratio of the HMW:
LMW units of adiponectin. As LMW adiponectin
was not evaluated, a potentially important piece of
the inflammatory role adiponectin plays in older mi-
graineurs may be missing from the current study. It is
possible that the LMW or HMW:LMW ratio may be
more sensitive of a marker of migraine in both
women and men.
Finally, migraine ascertainment is subject to recall
bias, and we were not able to exclude remitted migrai-
neurs or nonmigraine headaches (e.g., tension-type
headache) from our control group, which may have
biased our findings toward a null effect.37 While it
is possible that some migraineurs may have been part
of the nonmigraine control group, the migraine
groups more accurately reflect those with actual
migraine, therefore any associations observed are con-
servative estimates. This potential misclassification
could lead to attenuation of the results described,
especially in women.38 Unlike a clinic-based popula-
tion, expanding the modified ICHD criteria to the
ARIC cohort study has an unknown sensitivity for
detecting migraine, and has not been validated with
physician adjudication. Although aura was not a main
outcome, it was classified based on one question,
which can lead to misclassification of aura status.
Most importantly, participants were only asked about
visual symptoms, and aura can take many other
forms.
Despite these limitations, the present study
demonstrates that in older individuals, total adipo-
nectin is increased in migraineurs and that the risk
of migraine demonstrates a sex-specific effect such
that higher total adiponectin levels are associated
with a greater prevalence of migraine in older
men, but not older women. Additionally, leptin is
not associated with migraine in older men or
women. Further research examining the association
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between migraine and adiponectin, and particularly
LMW adiponectin and the HMW:LMW ratio in
older men and women inside and outside acute pain
states, is warranted.
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